Exact Sciences’ first mission is to help eradicate colon cancer. That mission is on the minds of our team members every single day, and March gives us an opportunity to be even louder about the work we do. Right now, our team members are preparing to take part in some big events to help spread awareness about the nation’s second deadliest cancer and the need for screening.
Cologuard gross margin reached 61 percent in fourth quarter
MADISON, Wis., Feb. 21, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $99.4 million and completed approximately 244,000 Cologuard tests during the year ended Dec. 31, 2016. Full-year 2016 revenues and Cologuard test volume grew 152 percent and 135 percent from 2015, respectively.
Cologuard offers health plans an opportunity to increase screening & improve quality ratings
MADISON, Wis., Feb. 2, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is included in the Medicare Advantage Advance Notice and Draft Call letter. Cologuard's inclusion in the final Star Ratings will allow Medicare Advantage plans to increase their Star Rating when patients complete Exact Sciences' non-invasive colon cancer screening test.